Interleukin inhibitors for psoriatic arthritis
References
Additional references
Arumugam R, McHugh NJ. Mortality and causes of death in psoriatic arthritis. Journal of Rheumatology. Supplement 2012;89:32‐5. [DOI: doi.org/10.3899/jrheum.120239]
Bruce IN, Gladman DD. Psoriatic arthritis: recognition and management. BioDrugs 1998;9:271‐8.
Buckley C, Cavill C, Taylor G, Kay H, Waldron N, Korendowych E, et al. Mortality in Psoriatic Arthritis – A single‐center study from the UK. Journal of Rheumatology 2010;37(10):2141‐4.
Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. Journal of the American Academy of Dermatology 2004;50(6):859‐66.
Dr. Christopher Cates EBM website. URL: www.nntonline.net. Visual Rx. Version 3. Dr. Christopher Cates EBM website. URL: www.nntonline.net, 2008.
Chung CP, Thompson JL, Koch GG, Amara I, Strand V, Pincus T. Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta‐analysis of discriminant capacities. Annals of the Rheumatic Diseases 2006;65(12):1602‐7.
Cuellar ML, Citera G, Espinoza LR. Treatment of psoriatic arthritis. Bailliere's Best Practice & Research. Clinical Rheumatology 1994;8(2):483‐98.
Davari P, Leo MS, Kamangar F, Fazel N. Ustekinumab for the treatment of psoriatic arthritis: an update. Clinical, Cosmetic and Investigational Dermatology 2014;7:243‐9.
Deeks JJ, Higgins JP, Altman DG (editors). Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis and Rheumatism 1995;38(6):727‐35.
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)‐a simple practical measure for routine clinical use. Clinical and Experimental Dermatology 1994;19(3):210‐6.
Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Clinical and Experimental Rheumatology 2005;23(5 Suppl 39):S93‐9.
Fransen J, van Riel PL. The disease activity score and the EULAR response criteria. Rheumatic Diseases Clinics of North America 2009;35(4):745‐57.
Fries J F, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis and Rheumatism 1980;23(2):137‐45.
Fénix‐Caballero S, Alegre‐del Rey E J, Castaño‐Lara R, Puigventós‐Latorre F, Borrero‐Rubio JM, López‐Vallejo JF. Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis. Journal of Clinical Pharmacy and Therapeutics 2013;38(4):286‐93.
Gan EY, Chong WS, Tey HL. Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents. BioDrugs 2013;27(4):359‐73.
Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. Journal of Rheumatology 1994;21(12):2286‐91.
Gaudio A, Corrado A, Santoro N, Maruotti N, Cantatore FP. Melkersson‐Rosenthal syndrome in a patient with psoriatic arthritis receiving etanercept. International Journal of Immunopathology and Pharmacology 2013;26(1):229‐33.
Ghogomu EA, Maxwell LJ, Buchbinder R, Rader T, Pardo Pardo J, Johnston RV, et al. Updated method guidelines for Cochrane musculoskeletal group systematic reviews and metaanalyses. Journal of Rheumatology 2014;41(2):194‐205.
Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis (PSA)‐an analysis of 220 patients. Quarterly Journal of Medicine 1987;62(238):127‐41.
Gladman DD, Stafford‐Brady F, Chang CH, Lewandowski K, Russell ML. Longitudinal study of clinical and radiological progression in psoriatic arthritis. Journal of Rheumatology 1990;17(6):809‐12.
Gladman DD, Cook RJ, Schentag C, Feletar M, Inman RI, Hitchon C, et al. The clinical assessment of patients with psoriatic arthritis: results of a reliability study of the spondyloarthritis research consortium of Canada. Journal of Rheumatology 2004;31(6):1126‐31.
Gladman DD. Mortality in psoriatic arthritis. Clinical and Experimental Rheumatology 2008;26(5 Suppl 51):S62‐5.
Goodfield M. Skin lesions in psoriasis. Bailliere's Best Practice & Research. Clinical Rheumatology 1994;8(2):295‐316.
McMaster University (developed by Evidence Prime). GRADEpro GDT: GRADEpro Guideline Development Tool. Available from: gradepro.org. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.
Griffiths CE. Therapy for psoriatic arthritis: sometimes a conflict for psoriasis. British Journal of Rheumatology 1997;36(4):409‐10.
Haroon M, Fitzgerald O. Pathogenetic overview of psoriatic disease. Journal of Rheumatology. Supplement 2012;89:7‐10.
Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis and Rheumatism 2008;59(5):686‐91.
Heiberg MS, Kaufmann C, Rodevand E, Mikkelsen K, Koldingsnes W, Mowinckel P, et al. The comparative effectiveness of anti‐TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study. Annals of the Rheumatic Diseases 2007;66(8):1038‐42.
Helliwell PS, Firth J, Ibrahim GH, Melsom RD, Shah I, Turner DE. Development of an assessment tool for dactylitis in patients with psoriatic arthritis. Journal of Rheumatology 2005;32(9):1745‐50.
Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis and Rheumatism 2008;58(1):15‐25.
Hemmati I, Kur J. Adalimumab‐associated antiphospholipid syndrome: a case report and review of the literature. Clinical Rheumatology 2013;32(7):1095‐8.
Heuft‐Dorenbosch L, Spoorenberg A, van Tubergen A, Landewé R, van ver Tempel H, Mielants H, et al. Assessment of enthesitis in ankylosing spondylitis. Annals of the Rheumatic Diseases 2003;62(2):127‐32.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60.
Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). Available from handbook.cochrane.org.
Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. Available from www.cochrane‐handbook.org.
Horreau C, Pouplard C, Brenaut E, Barnetche T, Misery L, Cribier B, et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. Journal of the European Academy of Dermatology and Venereology : JEADV 2013;27 Suppl3:12‐29.
Husted JA, Gladman D, Farewell VT, Cook RJ. Health‐related quality of life of patients with psoriatic arthritis: A comparison with patients with rheumatoid arthritis. Arthritis Care & Research 2001;45(2):151‐58.
Husted J A, Thavaneswaran A, Chandran V, Eder L, Rosen CF, Cook RJ, et al. Cardiovascular and other comorbidities in patients with psoriatic arthritis: A comparison with patients with psoriasis. Arthritis Care & Research 2011;63(12):1729‐35.
Jones G, Crotty M, Brooks P. Interventions for psoriatic arthritis. Cochrane Database of Systematic Reviews 2000, Issue 3. [DOI: 10.1002/14651858.CD000212]
Kirkham BW, Kavanaugh A, Reich K. Interleukin‐17A: a unique pathway in immune‐mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology 2014;141(2):133‐42.
Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. Journal of the American Academy of Dermatology 2004;51(4):563‐9.
Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiologica: Diagnosis (Stockh) 1977;18(4):481‐91.
Mander M, Simpson JM, McLellan A, Walker D, Goodacre JA, Dick WC. Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis. Annals of the Rheumatic Diseases 1987;46(3):197‐202.
Marguerie L, Flipo RM, Grardel B, Beaurain D, Duquesnoy B, Delcambre B. Use of disease‐modifying antirheumatic drugs in patients with psoriatic arthritis. Joint, Bone, Spine 2002;69(3):275‐81.
McKeage K. Ustekinumab: a review of its use in psoriatic arthritis. Drugs 2014;74(9):1029‐39.
McKenna SP, Doward LC, Whalley D, Tennant A, Emery P, Veale DJ. Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Annals of the Rheumatic Diseases 2004;63(2):162‐9.
Mease PJ, Ganguly R, Wanke L, Yu E, Singh A. How much improvement in functional status is considered important by patients with active psoriatic arthritis: applying the outcome measures in rheumatoid arthritis clinical trials (OMERACT) group guidelines. Annals of the Rheumatic Diseases 2004;63:391‐2.
Mease PJ, Gladman DD, Papp KA, Khraishi MM, Thaçi D, Behrens F, et al. Prevalence of rheumatologist‐diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. Journal of the American Academy of Dermatology 2013;69(5):729‐35.
Mease PJ. Inhibition of interleukin‐17, interleukin‐23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Current Opinion in Rheumatology 2015;27(2):127‐33.
Moll JM, Wright V. Psoriatic arthritis. Seminars in Arthritis and Rheumatism 1973;3(1):55‐78.
Mozaffari S, Nikfar S, Abdolghaffari AH, Abdollahi M. New biologic therapeutics for ulcerative colitis and Crohn's disease. Expert Opinion on Biological Therapy 2014;14(5):583‐600.
Nograles KE, Brasington RD, Bowcock AM. New insights into the pathogenesis and genetics of psoriatic arthritis. Nature Clinical Practice. Rheumatology 2009;5(2):83‐91.
Nüesch E, Trelle S, Reichenbach S, Rutjes AW, Tschannen B, Altman DG, et al. Small study effects in meta‐analyses of osteoarthritis trials: meta‐epidemiological study. BMJJuly 2010; Vol. 341:c3515.
Ogdie A, de Wit M, Callis Duffin K, Campbell W, Chau J, Coates LC, et al. Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA‐OMERACT Working Group. Journal of Rheumatology 2017;44(5):697‐700.
Olivieri I, D'Angelo S, Palazzi C, Lubrano E, Leccese P. Emerging drugs for psoriatic arthritis. Expert Opinion on Emerging Drugs 2010;15(3):399‐414.
Orbai AM, Mease PJ, de Wit M, Kalyoncu U, Campbell W, Tillett W, et al. Report of the GRAPPA‐OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting. Journal of Rheumatology 2016 May;43(5):965‐9.
Orbai AM, de Wit M, Mease P, Shea JA, Gossec L, Leung YY, et al. International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. Annals of the Rheumatic Diseases 2017;76(4):673‐80.
Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence. Journal of Investigative Dermatology 2013;133(2):377‐85.
Pincus T, Summey JA, Soraci Jr SA, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis and Rheumatism 1983;26(11):1346‐53.
Pollard LC, Choy EH, Gonzalez J, Khoshaba B, Scott DL. Fatigue in rheumatoid arthritis reflects pain, not disease activity. Rheumatology 2006;45(7):885‐9.
Prevoo ML, van Gestel AM, van T Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. British Journal of Rheumatology 1996;35(11):1101‐5.
Queiro‐Silva R, Torre‐Alonso JC, Tinture‐Eguren T, Lopez‐Lagunas I. A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis. Annals of the Rheumatic Diseases 2003;62(1):68‐70.
Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Saad AA, Symmons DP, Noyce PR, Ashcroft DM. Risks and benefits of tumor necrosis factor‐alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. Journal of Rheumatology 2008;35(5):883‐90.
Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JP, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Schünemann H, Oxman AD, Vist GE, Higgins JB, Deeks JJ, et al (editors). Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Sharp JT, Lidsky MD, Collins LC, Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis and Rheumatism 1971;14(6):706‐20.
Shbeeb M, Uramoto KM, Gibson LE, O'Fallon WM, Gabriel SE. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982‐1991. Journal of Rheumatology 2000;27(5):1247‐50.
Sheane BJ, Chandran V. Investigational drugs for treating psoriatic arthritis. Expert Opinion on Investigational Drugs 2014;23(7):1001‐16.
Soriano ER. The actual role of therapy with traditional disease‐modifying antirheumatic drugs in psoriatic arthritis. The Journal Rheumatology Supplement 2012;89:67‐70.
Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In Higgins JP, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available from handbook.cochrane.org.
Stolwijk C, van Onna, M, Boonen A, van Tubergen A. Global Prevalence of Spondyloarthritis: A Systematic Review and Meta‐Regression Analysis. Arthritis Care & Research 2016;68(9):1320‐31.
Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis and Rheumatism 2006;54(8):2665‐73.
Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta‐Analyses: The PRISMA Statement. BMJ 2009;339:b2535.
van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. Journal of Rheumatology 2000;27(1):261‐3.
van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis and Rheumatism 1996;39(1):34‐40.
Walsh JA, McFadden ML, Morgan MD, Sawitzke AD, Duffin KC, Krueger GG, et al. Work Productivity Loss and Fatigue in Psoriatic Arthritis. Journal of Rheumatology 2014;41(8):1670‐4.
Ware J E, Kosinski M. Interpreting SF‐36 summary health measures: a response. Quality of Life Research 2001;10(5):405‐20.
Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. Journal of Rheumatology 1993;20(3):557‐60.
Willkens RF, Williams HJ, Ward JR, Egger MJ, Reading JC, Clements PJ, et al. Randomized, double‐blind, placebo controlled trial of low‐dose pulse methotrexate in psoriatic arthritis. Arthritis and Rheumatism 1984;27(4):376‐81.
Zachariae H, Zachariae R, Blomqvist K, Davidsson S, Molin L, Mork C, et al. Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Dermato‐venereologica 2002;82(2):108‐13.
